Your browser is no longer supported. Please, upgrade your browser.
Settings
CBAY CymaBay Therapeutics, Inc. daily Stock Chart
CBAY [NASD]
CymaBay Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.36 Insider Own0.74% Shs Outstand69.30M Perf Week-1.88%
Market Cap397.09M Forward P/E- EPS next Y-1.69 Insider Trans0.00% Shs Float64.13M Perf Month-7.88%
Income-85.10M PEG- EPS next Q-0.37 Inst Own95.80% Short Float13.38% Perf Quarter-53.72%
Sales- P/S- EPS this Y-59.00% Inst Trans-3.10% Short Ratio6.31 Perf Half Y-44.31%
Book/sh3.44 P/B1.67 EPS next Y-13.40% ROA-37.10% Target Price16.09 Perf Year-52.99%
Cash/sh3.48 P/C1.65 EPS next 5Y- ROE-40.00% 52W Range4.82 - 14.00 Perf YTD-27.19%
Dividend- P/FCF- EPS past 5Y-15.50% ROI- 52W High-59.07% Beta1.25
Dividend %- Quick Ratio16.20 Sales past 5Y- Gross Margin- 52W Low18.88% ATR0.32
Employees43 Current Ratio16.20 Sales Q/Q- Oper. Margin- RSI (14)39.48 Volatility4.35% 5.59%
OptionableYes Debt/Eq0.00 EPS Q/Q-17.40% Profit Margin- Rel Volume0.21 Prev Close5.82
ShortableYes LT Debt/Eq0.00 EarningsAug 07 AMC Payout- Avg Volume1.36M Price5.73
Recom1.60 SMA20-5.18% SMA50-13.60% SMA200-41.46% Volume284,672 Change-1.55%
Jun-25-19Initiated Stifel Buy
Jun-12-19Upgrade Raymond James Outperform → Strong Buy
May-14-19Initiated Citigroup Buy $21
Feb-06-19Initiated B. Riley FBR Neutral $9
Jun-28-18Initiated Raymond James Outperform
Jun-06-18Reiterated H.C. Wainwright Buy $21 → $23
Feb-13-18Initiated Evercore ISI Outperform
Jan-25-18Resumed ROTH Capital Buy $27
Jan-24-18Reiterated H.C. Wainwright Buy $12 → $18
Aug-23-17Initiated Leerink Partners Outperform $12
Aug-18-17Initiated SunTrust Buy $15
Jul-20-17Reiterated Oppenheimer Outperform $8 → $15
Jun-23-17Initiated Oppenheimer Outperform $8
Jan-30-17Upgrade H.C. Wainwright Neutral → Buy $2.50 → $6
Jan-04-17Reiterated H.C. Wainwright Neutral $1.50 → $2.50
Jun-01-16Downgrade H.C. Wainwright Buy → Neutral $2.25
Sep-08-15Initiated H.C. Wainwright Buy $12
Jul-21-15Initiated Piper Jaffray Overweight $4
May-08-15Reiterated Stifel Buy $15 → $9
Jan-20-15Reiterated Stifel Buy $10 → $15
Aug-14-19 10:54AM  Edited Transcript of CBAY earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-12-19 08:46AM  3 Hot Healthcare Stocks That Wont Break the Bank TipRanks
Aug-09-19 02:01PM  CymaBay Therapeutics, Inc. (CBAY) Q2 2019 Earnings Call Transcript Motley Fool
Aug-07-19 04:10PM  CymaBay Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Aug-05-19 08:00AM  CymaBay Therapeutics Strengthens Management Team with Appointment of Janet Dorling as Chief Commercial Officer GlobeNewswire -6.93%
Jul-31-19 04:23PM  CymaBay Therapeutics to Report Second Quarter 2019 Financial Results on Wednesday, August 7 GlobeNewswire
Jun-18-19 08:00AM  CymaBay Therapeutics Announces IND to Commence a Clinical Study of Seladelpar to Treat Primary Sclerosing Cholangitis GlobeNewswire +8.16%
Jun-17-19 02:15PM  Bulls Walk the Market Up Slowly, but Keep One Eye on Fed TheStreet.com
10:08AM  Health Care Digest: Not-so-secret target of new UC-GSK alliance, East Bay toolmaker's big round and more American City Business Journals
08:00AM  CymaBay Therapeutics to Participate in the Raymond James Life Sciences and MedTech Conference GlobeNewswire
Jun-13-19 11:51AM  Hedge Funds Have Never Been This Bullish On CymaBay Therapeutics Inc (CBAY) Insider Monkey +9.40%
Jun-12-19 06:27PM  CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study Zacks
09:27AM  Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash Zacks
08:53AM  CymaBay Therapeutics Stock Plunged. Heres Why It Could Be Time to Buy Barrons.com
07:34AM  The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana Benzinga
Jun-11-19 12:25PM  Here's Why CymaBay Therapeutics Collapsed Today Motley Fool -45.45%
09:02AM  How Much Are CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Insiders Spending On Buying Shares? Simply Wall St.
08:58AM  CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors MarketWatch
08:30AM  CymaBay Therapeutics Plummets 40% Following Liver Disease Data Benzinga
07:00AM  CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis GlobeNewswire
Jun-10-19 02:50PM  Steven Cohen Takes an Interest in CymaBay Therapeutics GuruFocus.com
May-22-19 10:26AM  Options Traders Expect Huge Moves in CymaBay Therapeutics (CBAY) Stock Zacks
May-20-19 04:01PM  CymaBay Therapeutics Presents Data in Patients with Primary Biliary Cholangitis at DDW 2019 GlobeNewswire
May-18-19 09:50AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs Benzinga
May-16-19 09:07PM  Edited Transcript of CBAY earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-09-19 08:31PM  Hedge Funds Have Never Been This Bullish On CymaBay Therapeutics Inc (CBAY) Insider Monkey
May-08-19 04:05PM  CymaBay Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
08:00AM  CymaBay Therapeutics Announces Multiple Presentations at DDW 2019 GlobeNewswire
May-02-19 03:43PM  Genfit, Cymbay Hope to Crack Large Liver Disease Market GuruFocus.com
Apr-30-19 08:00AM  CymaBay Therapeutics to Report First Quarter 2019 Financial Results on Wednesday, May 8 GlobeNewswire
Apr-12-19 09:04AM  If You Had Bought CymaBay Therapeutics (NASDAQ:CBAY) Stock Three Years Ago, You Could Pocket A 703% Gain Today Simply Wall St.
08:00AM  CymaBay Therapeutics Presents Positive Phase 2 Data for Seladelpar in Patients with Primary Biliary Cholangitis at the International Liver Congress 2019 GlobeNewswire
Mar-27-19 08:00AM  CymaBay Therapeutics Announces Multiple Presentations During The International Liver Conference 2019 GlobeNewswire
Mar-25-19 07:00AM  Market Trends Toward New Normal in Louisiana-Pacific, The Michaels Companies, VEREIT, CymaBay Therapeutics, CareDx, and Harsco Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Mar-12-19 08:00AM  CymaBay Therapeutics to Present at Upcoming Investor Conferences in March GlobeNewswire
Mar-11-19 04:05PM  CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Mar-06-19 08:00AM  CymaBay Announces Pricing of Public Offering of Common Stock GlobeNewswire -5.20%
Mar-05-19 08:26PM  Edited Transcript of CBAY earnings conference call or presentation 28-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
04:01PM  CymaBay Announces Proposed Public Offering of Common Stock GlobeNewswire
Feb-28-19 11:24PM  CymaBay Therapeutics Inc (CBAY) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:05PM  CymaBay Reports Fourth Quarter and Fiscal Year End 2018 Financial Results and Provides Corporate Update GlobeNewswire
Feb-22-19 07:40AM  Factors of Influence in 2019, Key Indicators and Opportunity within Apple, United Continental, ImmunoGen, CymaBay Therapeutics, Granite Construction, and Flotek Industries New Research Emphasizes Economic Growth GlobeNewswire +11.39%
Feb-21-19 08:00AM  CymaBay Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results on Thursday, February 28 GlobeNewswire
Feb-20-19 08:00AM  CymaBay Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-19-19 08:00AM  CymaBay Therapeutics Announces Early Enrollment of a Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis GlobeNewswire
Feb-15-19 08:00AM  CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation by the FDA for the Treatment of Primary Biliary Cholangitis GlobeNewswire
Feb-07-19 09:20AM  CymaBay Therapeutics, Inc. (NASDAQ:CBAY): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
Jan-02-19 08:00AM  CymaBay Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-21-18 09:29AM  Have Insiders Been Buying CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares? Simply Wall St.
Dec-12-18 12:10AM  Hedge Funds Are Buying CymaBay Therapeutics Inc (CBAY) Insider Monkey
Nov-27-18 08:25AM  Report: Exploring Fundamental Drivers Behind ForeScout Technologies, GNC, Dova Pharmaceuticals, CymaBay Therapeutics, Adesto Technologies, and Clearside Biomedical New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-20-18 08:00AM  CymaBay Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-19-18 05:31AM  Edited Transcript of CBAY earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents -7.56%
Nov-13-18 08:00AM  CymaBay Therapeutics Presents Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC at The Liver Meeting® 2018 GlobeNewswire -14.19%
Nov-06-18 04:10PM  CymaBay Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Oct-30-18 04:05PM  CymaBay to Report Third Quarter 2018 Financial Results on Tuesday, November 6 GlobeNewswire +6.42%
08:00AM  CymaBay Announces the Initiation of the Seladelpar Global Phase 3 Registration Study (ENHANCE) for the Treatment of Primary Biliary Cholangitis and Additional Corporate Updates GlobeNewswire
Oct-22-18 11:57AM  Weekly CEO Buys Highlight GuruFocus.com
Oct-10-18 07:40AM  Report: Developing Opportunities within Brunswick, Pebblebrook Hotel Trust, Avaya, Braskem S.A, CymaBay Therapeutics, and The Blackstone Group Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-03-18 09:00AM  CymaBay Therapeutics Announces Additional Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC will be Presented During the Late-Breaking Session at The Liver Meeting® GlobeNewswire +7.82%
Sep-24-18 08:00AM  CymaBay Therapeutics to Participate in Upcoming Investor Conferences in October GlobeNewswire
Sep-17-18 03:40PM  Oppenheimers 7 Top Stock Picks for September Kiplinger
Aug-28-18 10:50AM  Oppenheimers 7 Top Stock Picks for September InvestorPlace
Aug-26-18 11:55PM  Edited Transcript of CBAY earnings conference call or presentation 9-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-14-18 08:00AM  CymaBay Therapeutics to Participate in Upcoming Investor Conferences in August and September GlobeNewswire
Aug-09-18 04:01PM  CymaBay Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Aug-02-18 08:00AM  CymaBay to Report Second Quarter 2018 Financial Results on Thursday, August 9 GlobeNewswire
07:23AM  New Strong Sell Stocks for August 2nd Zacks
Aug-01-18 08:00AM  Factors of Influence in 2018, Key Indicators and Opportunity within Five Prime Therapeutics, Akorn, The Blackstone Group, Avaya, Tractor Supply, and CymaBay Therapeutics New Research Emphasizes Economic Growth GlobeNewswire
Jul-26-18 06:34AM  New Strong Sell Stocks for July 26th Zacks -5.62%
Jul-11-18 08:06AM  New Strong Sell Stocks for July 11th Zacks
Jun-25-18 08:00AM  CymaBay Therapeutics Added to the Russell 3000® and Russell 2000® Indexes GlobeNewswire
Jun-19-18 08:00AM  CymaBay Therapeutics to Host Analyst and Investor Day on June 26, 2018 GlobeNewswire
May-15-18 03:52PM  Edited Transcript of CBAY earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-10-18 07:40AM  Wired News CymaBay Therapeutics Starts Phase-2b Clinical Trials of Seladelpar for Treatment of Patients with Non-Alcoholic Steatohepatitis ACCESSWIRE -5.79%
May-08-18 04:01PM  CymaBay Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
08:00AM  CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis GlobeNewswire
May-01-18 08:00AM  CymaBay to Report First Quarter 2018 Financial Results on Tuesday, May 8 GlobeNewswire
Apr-20-18 08:25AM  Report: Developing Opportunities within CymaBay Therapeutics, IAC/InterActiveCorp, Axcelis Technologies, La Quinta, Hornbeck Offshore Services, and Sprouts Farmers Market Future Expectations, Projections Moving into 2018 GlobeNewswire
Apr-13-18 07:30AM  Wired News CymaBay to Present Positive Results from Phase-2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at the EASL Liver Meeting 2018 ACCESSWIRE
Apr-12-18 09:37AM  CymaBay Therapeutics (CBAY) in Focus: Stock Moves 11.4% Higher Zacks
08:00AM  Todays Research Reports on Stocks to Watch: Keryx Biopharmaceuticals and CymaBay Therapeutics ACCESSWIRE
Apr-11-18 04:29PM  Could This Tiny Biotech Rout Intercept In Liver Disease Drugs? Investor's Business Daily +11.35%
07:47AM  CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress 2018 GlobeNewswire
Apr-09-18 12:05PM  5 Small-Cap Stocks With Explosive Upside Potential TheStreet.com
Mar-15-18 04:01PM  CymaBay Reports Fourth Quarter and Fiscal 2017 Financial Results and Provides Corporate Update GlobeNewswire -8.09%
12:15PM  CymaBay Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-09-18 11:02AM  High Growth Stocks To Invest In Simply Wall St.
Mar-06-18 08:00AM  CymaBay to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 15 GlobeNewswire
Mar-05-18 08:00AM  CymaBay Therapeutics to Participate in Upcoming Investor Conferences in March GlobeNewswire
Feb-16-18 07:35AM  Consolidated Research: 2018 Summary Expectations for Sunrun, CymaBay Therapeutics, Arrow Electronics, MGM Resorts International, Celanese, and Motorola Solutions Fundamental Analysis, Key Performance Indications GlobeNewswire
Feb-14-18 11:18AM  4 charts to watch as tech stocks rebound MarketWatch
Feb-06-18 08:00AM  CymaBay Therapeutics to Participate in Investor Conferences in February GlobeNewswire
Feb-01-18 04:01PM  CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
11:02AM  High Growth Stocks To Invest In Simply Wall St.
Jan-30-18 08:00AM  CymaBay Announces Pricing of Public Offering of Common Stock GlobeNewswire +6.29%
Jan-29-18 04:44PM  CymaBay Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-08-18 08:00AM  Enrollment Begins in Long-Term Extension Study of Seladelpar in Patients with Primary Biliary Cholangitis GlobeNewswire
08:00AM  CymaBay Therapeutics Receives $5 Million Milestone Payment for Arhalofenate from Kowa Pharmaceuticals America GlobeNewswire
Jan-02-18 04:01PM  CymaBay Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDFISCHER CARLDirectorFeb 07Option Exercise5.4011,67563,04511,675Feb 08 08:21 PM
GOLDFISCHER CARLDirectorFeb 07Sale9.0211,675105,3280Feb 08 08:21 PM
Shah SujalChief Executive OfficerDec 21Buy6.5410,00065,399110,000Dec 21 05:11 PM
EMSTER KURT VONDirectorDec 18Sale7.4353,492397,365131,036Dec 19 04:18 PM
EMSTER KURT VONDirectorDec 17Sale8.1788,889726,223184,528Dec 19 04:18 PM
Shah SujalChief Executive OfficerOct 15Buy9.905,00049,500100,000Oct 16 06:21 AM
Menold DanielVice President, FinanceAug 29Option Exercise5.005,00025,0005,000Aug 31 07:24 PM
Menold DanielVice President, FinanceAug 29Sale13.005,00065,0000Aug 31 07:24 PM